PT  - JOURNAL ARTICLE
ED  - Vidt, Donald G.
AU  - Brzezinski, Aaron
AU  - Rankin, George B.
AU  - Seidner, Douglas L.
AU  - Lashner, Bret A.
TI  - Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease
DP  - 1995 Sep 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 317--323
VI  - 62
IP  - 5
4099  - http://www.ccjm.org/content/62/5/317.short
4100  - http://www.ccjm.org/content/62/5/317.full
SO  - Cleve Clin J Med1995 Sep 01; 62
AB  - SUMMARY Although sulfasalazine, a 5-aminosalicylic acid (5-ASA) agent, is still the anti-inflammatory agent of choice for ulcerative colitis and Crohn's disease, newer formulations, which release drug to specific regions of the colon for maximal efficacy, also can be appropriate first-line agents. This article reviews recent clinical studies of therapy with older and newer 5-ASA formulations.